Welcome to our dedicated page for Cellyan Biotechnology Co SEC filings (Ticker: HKPD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cellyan Biotechnology Co., Ltd. filings document the foreign private issuer’s OTC pharmaceutical cross-border e-commerce supply chain operations, public-company governance, and capital structure. Form 6-K reports include interim consolidated financial statements, operating and financial review materials, and disclosures related to the company’s Class A ordinary shares.
The filing record also covers annual general meeting materials, board and officer changes, independent director appointments, amended constitutional documents, an equity incentive plan, share repurchase and Class B ordinary share matters, Nasdaq minimum bid-price compliance notices, and financing arrangements involving units, warrants, and resale registration rights.
Cellyan Biotechnology filed a Form F-3 shelf registration to offer up to $200,000,000 of Class A ordinary shares, debt securities, warrants, rights and units, to be sold from time to time after the effective date. The prospectus discloses a public float of $24.95 million (based on 34,181,490 shares held by non-affiliates) and states the Company may not sell a primary offering exceeding one-third of that public float under Form F-3 rules. The filing notes Nasdaq minimum bid price noncompliance with a compliance deadline of July 13, 2026, describes governance and operational risks from its Cayman/Hong Kong holding-company structure and summarizes PRC/Hong Kong regulatory and PCAOB inspection-related risks. Key corporate actions since the prior annual report are summarized, including management changes, an authorized capital increase and class conversion actions reflected in the amended memorandum and articles.
Cellyan Biotechnology Co., Ltd director CHAN Kam Leung filed an initial Form 3, which is a required insider ownership report when someone becomes a director or other reporting person. This filing lists their insider status with the company but shows no reported transactions or derivative positions.
Cellyan Biotechnology Co., Ltd director Wong Lap Sun has filed an initial Form 3 reporting beneficial ownership in the company. The filing shows direct ownership of 18,468 Class A Ordinary Shares as of the reported date, without any associated buy or sell transaction.
Cellyan Biotechnology Co., Ltd has an initial ownership report for Chief Strategy Officer Wang Zifeng under a Form 3 filing. The data shows no reported common stock or derivative holdings and no buy, sell, or other insider transactions associated with this officer in the reported period.
Cellyan Biotechnology Co., Ltd filed an initial Form 3 for CFO Liu Shu. This filing identifies Liu Shu as an officer of the company but does not report any buy, sell, or other insider transactions, and shows no derivative positions or holding entries at this time.
Cellyan Biotechnology Co., Ltd filed an initial insider ownership report for director Zhou Mike Yao on Form 3. This filing identifies him as a director of the company and subject to insider reporting rules, but does not list any specific share holdings or recent transactions in the provided data.
Cellyan Biotechnology Co., Ltd director Wu Jingyan has filed an initial Form 3, which is the SEC’s statement of beneficial ownership for company insiders. This filing establishes Wu’s status as a director and provides a baseline disclosure of holdings, with no transactions reported in this data.
Cellyan Biotechnology Co., Ltd insider Liang Chenyu Andy, who serves as CEO and Director, filed an initial ownership report with no reported transactions. The Form 3 data show zero shares bought, sold, acquired, or disposed, indicating only a baseline disclosure of status as a reporting person.
Registration for resale of up to 12,499,986 Class A Ordinary Shares by existing holders is being registered on Form F-1; these are resale shares the company will not receive proceeds from. The prospectus states the Offered Shares were issued in a March 2026 private placement and may be sold from time to time.
The filing notes the Class A Ordinary Shares trade on Nasdaq under the symbol HKPD and shows a last reported sale price of $0.65 per share as of March 26, 2026. It highlights material governance and operational points: Cellyan Biotechnology is a controlled company (majority voting power held by Ms. Liying Wang), it completed a dual-class restructuring and share repurchase, and it received a Nasdaq notice for minimum bid-price noncompliance with a compliance deadline of July 13, 2026.